Systemic lupus erythematosus (SLE), the embodiment of a multi-organ autoimmune disease, results from hyperactivation of host-defence pathways and immune recognition of the most fundamental building blocks of life. In 2018, key advances have placed intestinal immunity and dysregulated expansions of candidate pathobionts at the forefront of SLE pathogenesis.
The Microbiome and Systemic Lupus Erythematosus
Systemic Lupus Erythematosus and dysbiosis in the
microbiome: cause or effect or both?
“Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort
Soluble PD-1: Predictive, Prognostic,
and Therapeutic Value for Cancer
The Tellurium-based Immunomodulator, AS101 Ameliorates Adjuvant-Induced Arthritis in Rats in Clinical & Experimental Immunology
Are Farming and Animal Exposure Risk Factors for the
Development of Granulomatosis with Polyangiitis?
Environmental Risk Factors Revisited.
The utility of PET/CT in large vessel
Cancer and autoimmune diseases are the two devastating conditions that together constitute a leading health problem worldwide. The rising burden of these disorders in the developing world demands a multifaceted approach to address the challenges it poses.
In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L, such as tetrahydrocannabinol
-THC) and cannabidiol (CBD), and their efects on infammation and cancer-related pain.